Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

USPTO issues patent to EndoSphere's noninvasive device for treatment of obesity

EndoSphere Inc., a medical technology company that holds 23 U.S. and international issued and pending patents, announced today that the U.S. Patent and Trademark Office has issued the company a patent covering the use of its endoscopically implantable devices for the treatment of metabolic diseases, including obesity and type 2 diabetes.

16 Jun 2011

Liver stiffness measurement could replace liver biopsy for evaluation of hepatitis C

Non-invasive tests for liver fibrosis, such as liver stiffness measurement or the FibroTest, can predict survival of patients with chronic hepatitis C, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.

15 Jun 2011

Alios, Vertex sign worldwide license agreement to develop new hepatitis C combination medicines

Vertex Pharmaceuticals Incorporated and Alios BioPharma, Inc. today announced an exclusive worldwide licensing agreement that will add two distinct nucleotide analogues to Vertex's hepatitis C portfolio.

13 Jun 2011

German hospital adopts Luminex new diagnostic assay to manage current E.coli outbreak

Luminex Corporation and the Kliniken der Stadt Koln, Institute of Pathology and Institute for Hygiene today announced that Luminex's newly released xTAG Gastrointestinal Pathogen Panel (GPP) is being used successfully as a first-line screen for patients at Kliniken der Stadt Koln suspected of having an E. coli infection.

From Luminex 10 Jun 2011

AGA honors outstanding high school students with 2011 research fellowship awards

The American Gastroenterological Association (AGA) Research Foundation has announced the 2011 Student Research Fellowship Award recipients. Funded by The Eli and Edythe Broad Foundation, the awards are intended to stimulate interest in research careers in digestive diseases.

10 Jun 2011

Repligen total revenue increases 30% to $27,291,000 for fiscal year 2011

Repligen Corporation today reported results for the fourth quarter and fiscal year 2011, ended March 31, 2011.

9 Jun 2011

Hepatitis C virus (HCV)-associated liver disease after liver transplantation

Hepatitis C virus (HCV)-associated liver disease continues to be the most common indication for liver transplantation (LT) in the United States accounting for nearly 50% of all liver transplants. Recurrence is universal in patients viremic at the time of transplantation with histological hepatitis developing in the majority of patients. Although the natural history of recurrent HCV is difficult to predict, it is widely accepted that cirrhosis from recurrent HCV occurs in up to 30% of patients within five years of transplantation.

8 Jun 2011

Topline results from 4SC vidofludimus Phase IIb trial against rheumatoid arthritis

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced topline results from its randomised, double-blind, placebo-controlled Phase IIb clinical trial COMPONENT in RA.

8 Jun 2011

Overweight increases risk of liver cirrhosis in men

Overweight carries a greatly increased risk of cirrhosis of the liver in men, reveals a new study from the Sahlgrenska Academy. "Given the increasing problem of overweight in Sweden, there is reason to fear that more people will develop cirrhosis of the liver," says Jerzy Kaczynski, docent at the University of Gothenburg and doctor at Sahlgrenska University Hospital.

8 Jun 2011

Hepatitis C patients with chronic liver disease may benefit from drinking coffee during treatment

Advanced hepatitis C patients with chronic liver disease may benefit from drinking coffee during treatment, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.

8 Jun 2011

Shire Canada receives expanded indication for MEZAVANT for treatment of ulcerative colitis

Shire Canada Inc., a division of Shire plc, the global specialty biopharmaceutical company, is proud to announce that MEZAVANT® (mesalamine delayed and extended release tablets), the first and only once-daily mesalamine indicated for the induction of clinical and endoscopic remission in patients with mild-to-moderate, active ulcerative colitis (UC), has received an expanded indication to include maintenance of clinical and endoscopic remission (mucosal healing) in patients with ulcerative colitis.

7 Jun 2011

Trifunctional antibody Catumaxomab triggers vaccination effect against cancer

TRION Pharma GmbH has announced that the results from two different studies demonstrate catumaxomab’s capacity to activate the immune system in a way that can otherwise only be achieved through vaccination. The data were obtained by two independent research teams using catumaxomab in malignant ascites and gastric cancer, respectively. The results were recently presented at the annual meeting of the American Society of Clinical Oncology (ASCO).

6 Jun 2011

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

Novartis announced new data today showing a significant improvement in both recurrence-free survival and overall survival for patients taking Gleevec® (imatinib mesylate)* tablets for three years after surgery to remove KIT (CD117)-positive gastrointestinal stromal tumors (KIT+ GIST) compared to one year of treatment. These data will be presented at the 47th American Society of Clinical Oncology (ASCO) plenary session on Sunday, June 5.

6 Jun 2011

EUS-guided GI biopsies with Cook Medical's new, large-core biopsy needle overcomes limitations

Results from a multicenter European study suggest that a new, large-core biopsy needle designed for use with an endoscopic ultrasound (EUS) scope may help to overcome limitations of current EUS methods for biopsies of lesions in the gastrointestinal (GI) tract and surrounding tissue.

6 Jun 2011

Ganeden Biotech sells Sustenex and Digestive Advantage to Schiff for $40 million

Ganeden Biotech announced the sale of its leading Sustenex® and Digestive Advantage® brands of probiotic dietary supplements to Schiff Nutrition International, Inc. for $40 million in cash. Ganeden will also receive royalties on Schiff products containing GanedenBC30™.

6 Jun 2011

American College of Gastroenterology offers resources on foodborne illness, tips for food safety

For consumers in the United States concerned by the outbreak of E. coli in Europe, the American College of Gastroenterology offers background on foodborne illness, tips for food safety, and expert insight from its resources on digestive health on what to do in the case of foodborne illness.

4 Jun 2011

Majority of patients with ulcerative colitis eager to undergo fecal microbiota transplantation

The first study of the social and ethical issues associated with a provocative approach to treatment for ulcerative colitis has found that the majority of potential patients are eager for what is now called "fecal microbiota transplantation" to become available, although many have concerns about donor selection, screening, and methods of delivery.

3 Jun 2011

SHEA, ASGE update Flexible gastrointestinal endoscope guideline

The American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Healthcare Epidemiology of America (SHEA) have updated their 2003 joint guideline for reprocessing gastrointestinal endoscopes to reaffirm reprocessing methods and take into account evolved technology and disinfection systems.

2 Jun 2011

Repligen announces completion of RG1068 pre-New Drug Application meeting with U.S. FDA

Repligen Corporation today announced that the Company has concluded a pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration related to its lead product candidate, RG1068 for improvement of magnetic resonance imaging of the pancreas.

2 Jun 2011

Niiki Pharma to present NKP-1339 Phase I trial against metastatic cancer at ASCO 2011

Niiki Pharma announced today that it will present interim data from the ongoing Phase I clinical study for its lead product, NKP-1339, at the 2011 American Society for Clinical Oncology meeting in Chicago, IL.

2 Jun 2011

Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

USPTO issues patent to EndoSphere's noninvasive device for treatment of obesity

Liver stiffness measurement could replace liver biopsy for evaluation of hepatitis C

Alios, Vertex sign worldwide license agreement to develop new hepatitis C combination medicines

German hospital adopts Luminex new diagnostic assay to manage current E.coli outbreak

AGA honors outstanding high school students with 2011 research fellowship awards

Repligen total revenue increases 30% to $27,291,000 for fiscal year 2011

Hepatitis C virus (HCV)-associated liver disease after liver transplantation

Topline results from 4SC vidofludimus Phase IIb trial against rheumatoid arthritis

Overweight increases risk of liver cirrhosis in men

Hepatitis C patients with chronic liver disease may benefit from drinking coffee during treatment

Shire Canada receives expanded indication for MEZAVANT for treatment of ulcerative colitis

Trifunctional antibody Catumaxomab triggers vaccination effect against cancer

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

EUS-guided GI biopsies with Cook Medical's new, large-core biopsy needle overcomes limitations

Ganeden Biotech sells Sustenex and Digestive Advantage to Schiff for $40 million

American College of Gastroenterology offers resources on foodborne illness, tips for food safety

Majority of patients with ulcerative colitis eager to undergo fecal microbiota transplantation

SHEA, ASGE update Flexible gastrointestinal endoscope guideline

Repligen announces completion of RG1068 pre-New Drug Application meeting with U.S. FDA

Niiki Pharma to present NKP-1339 Phase I trial against metastatic cancer at ASCO 2011

Microbiology eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

Microbiology eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in